On March 24, 2026, the Froedtert & the Medical College of Wisconsin (MCW) Cancer Network announced a significant milestone reflecting both clinical progress and expanded access to care. The team delivered the first-ever proton therapy treatment in the state of Wisconsin—marking a meaningful step forward for patients across the region who can now receive this highly specialized form of radiation therapy closer to home.

The first patient treated was a young adult with a central nervous system tumor. Cases like this underscore the value of proton therapy—its ability to precisely target tumors while minimizing exposure to surrounding healthy tissue is especially critical for complex conditions and for younger patients, where long-term outcomes matter deeply.

The program is powered by the MEVION S250i Proton Therapy System^®, installed within the Froedtert & MCW Clinical Cancer Center in Milwaukee. The system’s compact design and advanced capabilities, including HYPERSCAN^® pencil beam scanning, enable highly tailored treatments while integrating seamlessly into existing clinical workflows.

With this milestone, the Froedtert & MCW Cancer Network becomes the first provider in Wisconsin to offer proton therapy. In partnership with Children’s Wisconsin, the program will serve both adult and pediatric patients—expanding access to advanced care for some of the most sensitive and challenging cancer cases.

“We are proud to support the Froedtert & MCW team as they bring this capability to their patients and community,” said Tina Yu, PhD, CEO and President of Mevion Medical Systems. “Their leadership and commitment to innovation are evident in this achievement, and we look forward to seeing the continued impact of their program.”

About Mevion Medical Systems

Mevion Medical Systems is the leading provider of compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy. Since 2013, Mevion’s compact proton therapy single-room systems have been used by leading cancer centers for treating patients. Mevion’s series of products, including the flagship MEVION S250i and MEVION S250-FIT™ with HYPERSCAN pencil beam scanning, represent the world’s most compact proton therapy systems that eliminate the obstacles of size, complexity, and cost. Mevion is headquartered in Littleton, Massachusetts with a presence in Europe and Asia. For more information, please visit www.mevion.com.

Media Contact:
Jacqueline Abner-Pongratz
Jacqueline.Pongratz@Mevion.com